{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:55:42Z","timestamp":1789188942619,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clgc.2013.05.002","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T20:01:06Z","timestamp":1373659266000},"page":"441-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["\u201cReal World\u201d Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Michael R.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Korytowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald T.","family":"Kirkendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Stepanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy P.","family":"Abernethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2013.05.002_bib1","first-page":"10","article-title":"Cancer Statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2013.05.002_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ctrv.2010.08.005","article-title":"Sunitinib for the treatment of metastatic renal cell carcinoma","volume":"37","author":"Oudard","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2013.05.002_bib3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1464-410X.2009.08987.x","article-title":"Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms","volume":"104","author":"Mulders","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2013.05.002_bib4","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"3556","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.002_bib6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.002_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.05.002_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.05.002_bib9","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.05.002_bib10","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa vs. interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1464-410X.2009.08563.x","article-title":"Optimal management of metastatic renal cell carcinoma: an algorithm for treatment","volume":"104","author":"Bellmunt","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2013.05.002_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006017.pub2","article-title":"Targeted therapy for advanced kidney cancer","author":"Coppin","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"suppl 1","key":"10.1016\/j.clgc.2013.05.002_bib14","first-page":"S1","article-title":"NCCN Task Force Report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy","volume":"9","author":"Hudes","year":"2011","journal-title":"J\u00a0Natl Comp Canc Netw"},{"issue":"suppl 2","key":"10.1016\/j.clgc.2013.05.002_bib15","first-page":"32","article-title":"Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies","volume":"16","author":"Molina","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2013.05.002_bib16","unstructured":"National Cancer Institute. Kidney cancer. Available at: http:\/\/www.cancer.gov\/cancertopics\/types\/kidney. Accessed: September 6,\u00a02011."},{"key":"10.1016\/j.clgc.2013.05.002_bib17","article-title":"\u201cReal world\u201d treatment of metastatic renal cell carcinoma: Overall survival by mechanism of action and sequence of treatment in a joint community-academic cohort","author":"Harrison","year":"2013","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2013.05.002_bib18","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1200\/JCO.2010.28.5478","article-title":"Rapid-learning system for cancer care","volume":"28","author":"Abernethy","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib19","series-title":"Clinical Trials in Oncology","author":"Green","year":"1997"},{"key":"10.1016\/j.clgc.2013.05.002_bib20","series-title":"Applied Survival Analysis: Regression Modeling of Time to Event Data","author":"Hosmer","year":"2008"},{"key":"10.1016\/j.clgc.2013.05.002_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib22","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-11-0553","article-title":"Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group","volume":"17","author":"Manola","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clgc.2013.05.002_bib23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the memorial sloan- kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib24","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of\u00a0670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib25","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.002_bib26","article-title":"Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4\/2 vs. continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial","volume":"29","author":"Motzer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","article-title":"NCCN clinical practice guidelines in oncology: Kidney Cancer","volume":"7","author":"Motzer","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2013.05.002_bib28","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer","author":"National Comprehensive Cancer Network","year":"2012"},{"key":"10.1016\/j.clgc.2013.05.002_bib29","unstructured":"National Cancer Institute. FDA approval for everolimus. 2011; http:\/\/www.cancer.gov\/cancertopics\/druginfo\/fda-everolimus. Accessed: December 5,\u00a02011."},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.002_bib30","article-title":"A\u00a0multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials","volume":"30","author":"Heng","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.002_bib31","article-title":"Axitinib vs. sorafenib as firstline therapy in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Hutson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2013.05.002_bib32","article-title":"Tivozanib vs. sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial","volume":"30","author":"Motzer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib33","doi-asserted-by":"crossref","unstructured":"Hutson TE, Escudier B, Esteban E, et\u00a0al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Paper presented at: EMSO Congress 2012; September 28-October 2, 2012; Vienna, Austria.","DOI":"10.1016\/S0923-7534(20)34327-1"},{"key":"10.1016\/j.clgc.2013.05.002_bib34","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Hutson TE, Reeves J, et\u00a0al. Randomized, open label, phase III trial of pazopanib vs. sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the cOMPARZ Trial. Paper presented at: EMSO Congress 2012; September 28-October 2, 2012; Vienna, Austria.","DOI":"10.1016\/S0923-7534(20)34325-8"},{"key":"10.1016\/j.clgc.2013.05.002_bib35","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.05.002_bib36","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731300133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731300133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:22:24Z","timestamp":1761564144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731300133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S155876731300133X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2013.05.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cReal World\u201d Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2013.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}